Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine or tenofovir
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lamivudine and tenofovir are antiretroviral medications used primarily in the treatment of human immunodeficiency virus type 1 (HIV‑1) infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while tenofovir is a nucleotide reverse transcriptase inhibitor. Both drugs act by inhibiting the activity of HIV reverse transcriptase, an enzyme necessary for viral replication. They are often used together as part of combination therapy to reduce viral load and improve immune function in people living with HIV[4][5][6]. Tenofovir is also approved for the treatment of hepatitis B virus infection. These drugs do not cure HIV or AIDS but help manage the disease when taken as prescribed[1][4]. Lamivudine was developed by GlaxoSmithKline; tenofovir was developed by Gilead Sciences.
- Brand names
- Epivir (lamivudine)Viread (tenofovir)Truvada (tenofovir combination)Cimduo (lamivudine/tenofovir combination)Symfi (combination with efavirenz, lamivudine, and tenofovir)Atripla (combination with efavirenz, emtricitabine, and tenofovir)
- Other names
- lamivudine3TCtenofovir disoproxil fumarateTDF
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on lamivudine or tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine or tenofovir.